POSB120 Economic Assessment of Ribociclib for the Treatment of Postmenopausal Patients with Advanced Breast Cancer HR-Positive, HER2-Negative.
Abstract
Authors
M Velásquez L Bustos Medina C Zagarra Chacón R Rojas
M Velásquez L Bustos Medina C Zagarra Chacón R Rojas
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now